Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042
Piperdi, B.; Ayers, M.; Pietanza, M. C.; Mok, T. S. K.; Turna, H. Z.; Herbst, R. S.; Lopes, G.; Kowalski, D. M.; Kasahara, K.; Wu, Y-L.; De Castro, G.; Cho, B. C.; Cristescu, R.; Aurora-Garg, D.; Lunceford, J.; Kobie, J.